Amy M. Fremgen
American College of Surgeons
Network
Latest external collaboration on country level. Dive into details by clicking on the dots.
Publication
Featured researches published by Amy M. Fremgen.
Journal of The American College of Surgeons | 1999
Stephen F. Sener; Amy M. Fremgen; Herman R. Menck; David P. Winchester
BACKGROUND The National Cancer Database is an electronic registry system sponsored jointly by the American College of Surgeons Commission on Cancer and the American Cancer Society. Patients diagnosed with pancreatic adenocarcinoma from 1985 to 1995 were analyzed for trends in stage of disease, treatment patterns, and outcomes. STUDY DESIGN Seven annual requests for data were issued by the National Cancer Database from 1989 through 1995. Data on 100,313 patients were voluntarily submitted using a standardized reporting format. RESULTS The anatomic site distribution was: head, 78%; body, 11%; and tail, 11%. The ratios of limited to advanced disease (Stage I/Stage IV) were 0.70 for tumors in the head, 0.24 for body tumors, and 0.10 for tail tumors. Of all patients, 83% did not have a surgical procedure and 58% did not have cancer-directed treatment. Resection was done for 9,044 (9%) patients, including 22% of those with Stage I disease. The overall 5-year survival rate was 23.4% for patients who had pancreatectomy, compared with 5.2% for those who had no cancer-directed treatment. CONCLUSIONS Overall survival rates for pancreatic cancer have not changed in 2 decades. A small minority of patients presented with limited, resectable disease, but the best survival rates per stage were achieved after surgical resection. Five-year survival rates after resection reported herein corroborated the improved survival rates of more recent large, single institution studies.
Cancer | 2000
Scott A. Hundahl; Blake Cady; Myles P. Cunningham; Ernest L. Mazzaferri; Rosemary F. McKee; Juan Rosai; Jatin P. Shah; Amy M. Fremgen; Andrew K. Stewart; Simon Hölzer
The American College of Surgeons Commission on Cancer (CoC) has conducted national Patient Care Evaluation (PCE) studies since 1976.
Journal of The American College of Surgeons | 2000
John M. Daly; Willard A Fry; Alex G. Little; David P. Winchester; Rosemary F. McKee; Andrew K. Stewart; Amy M. Fremgen
BACKGROUND The last two decades have seen changes in the prevalence, histologic type, and management algorithms for patients with esophageal cancer. The purpose of this study was to evaluate the presentation, stage distribution, and treatment of patients with esophageal cancer using the National Cancer Database of the American College of Surgeons. STUDY DESIGN Consecutively accessed patients (n = 5,044) with esophageal cancer from 828 hospitals during 1994 were evaluated in 1997 for case mix, diagnostic tests, and treatment modalities. RESULTS The mean age of patients was 67.3 years with a male to female ratio of 3:1; non-Hispanic Caucasians made up most patients. Only 16.6% reported no tobacco use. Dysphagia (74%), weight loss (57.3%), gastrointestinal reflux (20.5%), odynophagia (16.6%), and dyspnea (12.1%) were the most common symptoms. Approximately 50% of patients had the tumor in the lower third of the esophagus. Of all patients, 51.6% had squamous cell histology and 41.9% had adenocarcinoma. Barretts esophagus occurred in 777 patients, or 39% of those with adenocarcinoma. Of those patients that underwent surgery initially, pathology revealed stage I (13.3%), II (34.7%), III (35.7%), and IV (12.3%) disease. For patients with various stages of squamous cell cancer, radiation therapy plus chemotherapy were the most common treatment modalities (39.5%) compared with surgery plus adjuvant therapy (13.2%). For patients with adenocarcinoma, surgery plus adjuvant therapy were the most common treatment methods. Disease-specific overall survival at 1 year was 43%, ranging from 70% to 18% from stages I to IV. CONCLUSIONS Cancer of the esophagus shows an increasing occurrence of adenocarcinoma in the lower third of the esophagus and is frequently associated with Barretts esophagus. Choice of treatment was influenced by tumor histology and tumor site. Multimodality (neoadjuvant) therapy was the most common treatment method for patients with esophageal adenocarcinoma. The use of multimodality treatment did not appear to increase postoperative morbidity.
Cancer | 1999
Scott A. Hundahl; Irvin D. Fleming; Amy M. Fremgen; Herman R. Menck
In combination with other Commission on Cancer programs, the National Cancer Data Base (NCDB), a national electronic registry system currently capturing > 60% of incident cancers in the U. S., offers a working example of voluntary, accurate, cost‐effective “outcomes management” on a both a local and national scale. In addition, it is proving to be of particular value in capturing clinical information concerning rare cancers.
Cancer | 1997
Alfred Grovas; Amy M. Fremgen; Amanda Rauck; Frederick B. Ruymann; Carol L. Hutchinson; David P. Winchester; Herman R. Menck
Patterns of and progress against childhood cancer have been reported on multi‐institution, regional, national, and international bases by several sources in the past. These sources have included clinical cooperative group trials and population‐based registries. In general, the population‐based surveys have excluded brain tumors of either benign or uncertain behavior. The authors of this article investigated the patterns of data reported for the period 1985‐1993, motivated by their interest in assessing the potential of National Cancer Data Base (NCDB) data to 1) facilitate individual institution review and 2) cover institutions that are not members of the Pediatric Oncology Group or the Childrens Cancer Group, which are both national clinical cooperative groups.
American Journal of Surgery | 1990
Myles P. Cunningham; Rosemary B. Duda; Wendy Recant; Joan S. Chmiel; JoAnne Sylvester; Amy M. Fremgen
Since 1975, the American Cancer Society, Illinois Division, has published end results of major cancer sites drawn from patient data contributed voluntarily by hospital cancer registries throughout the state. The current study was undertaken, in part, to apprehend information regarding contested areas in the management of patients having differentiated (papillary/follicular) thyroid cancer. A total of 2,282 patients with either papillary or follicular carcinoma of the thyroid from 76 different Illinois hospitals and providing 10 years of follow-up information (life-table analysis) were retrospectively analyzed for demographic, disease, and treatment-related predictors of survival. Multivariate analysis using the Cox proportional hazards method was made for stage, age, race, sex, morphology, history of radiation exposure, presence of positive lymph nodes, initial surgical treatment, postoperative iodine 131 therapy, and replacement/suppressive thyroid hormone treatment. Statistically significant (p less than or equal to 0.05) predictors of favorable survival after thyroid cancer were low stage (I and II), young age (less than 50 years), white race, female sex, and the administration, postoperatively, of either thyroid hormone or radioactive iodine. Factors that had no influence on survival were lymph node status, choice of initial surgical treatment, and a history of prior irradiation. We suggest that where a prospective clinical trial is impracticable, a retrospective analysis of a large and detailed database, such as that available from cooperating hospital-based tumor registries, may yet provide useful insights to solutions of cancer management problems.
Cancer | 1996
Erna Busch; Margaret Kemeny; Amy M. Fremgen; Robert T. Osteen; David P. Winchester; Rosemarie E. Clive
The elderly represent a large proportion of the women with breast cancer. However, there is a lack of information regarding breast cancer care in the elderly.
Laryngoscope | 1997
Henry T. Hoffman; Lucy H. Karnell; Jatin P. Shah; Stephan Ariyan; G. Stephen Brown; Willard E. Fee; Andrew G. Glass; Helmuth Goepfert; Robert H. Ossoff; Amy M. Fremgen
A survey was conducted to identify demographics and standards of care for treatment of hypopharyngeal squamous cell carcinoma in the United States. Data were accrued from voluntary submission of cancer registry and medical chart information from 769 hospitals representing 2939 cases diagnosed from 1980 to 1985 and 1990 to 1992. Clinical findings, diagnostic procedures employed, treatment practices, and outcome are presented. Overall, 5‐year disease‐specific survival was 33.4%, which segregated to 63.1% (stage I), 57.5%(stage II), 41.8% (stage III), and 22% (stage IV). Survival was best for patients treated with surgery only (50.4%), similar with combined surgery and irradiation (48%), and worse with irradiation only (25.8%). This analysis provides a standard to which current treatment practice and future clinical trials may be compared.
Cancer | 1996
Walter B. Jones; Hugh M. Shingleton; Anthony H. Russell; Amy M. Fremgen; Rosemarie E. Clive; David P. Winchester; Joan S. Chmiel
The American College of Surgeons conducted a national patient care and evaluation study of invasive cervical carcinoma in pregnant patients.
CA: A Cancer Journal for Clinicians | 2001
Stephen J. Shochat; Amy M. Fremgen; Sharon B. Murphy; Carol Hutchison; Sarah S. Donaldson; Gerald M. Haase; Arthur Provisor; Rosemarie E. Clive‐Bumpus; David P. Winchester
Cancer is still the chief cause of death by disease in children, ages one to 14. As improved survival rates have been reported for pediatric cancer patients who are treated on controlled clinical trials, it is important to understand the national utilization of such protocols.